Charles Schwab Trust Co Reduces Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Charles Schwab Trust Co lessened its stake in shares of Eli Lilly and Company (NYSE:LLY) by 21.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 226 shares of the company’s stock after selling 63 shares during the quarter. Charles Schwab Trust Co’s holdings in Eli Lilly and Company were worth $200,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of LLY. Fermata Advisors LLC grew its holdings in shares of Eli Lilly and Company by 2.3% during the third quarter. Fermata Advisors LLC now owns 1,264 shares of the company’s stock worth $1,120,000 after purchasing an additional 29 shares during the last quarter. JGP Wealth Management LLC increased its position in Eli Lilly and Company by 2.3% during the third quarter. JGP Wealth Management LLC now owns 1,752 shares of the company’s stock worth $1,552,000 after buying an additional 40 shares during the period. Strong Tower Advisory Services increased its position in Eli Lilly and Company by 2.4% during the third quarter. Strong Tower Advisory Services now owns 9,601 shares of the company’s stock worth $8,506,000 after buying an additional 227 shares during the period. BWM Planning LLC purchased a new stake in Eli Lilly and Company in the third quarter valued at approximately $912,000. Finally, Scott Capital Advisors LLC boosted its holdings in shares of Eli Lilly and Company by 2.4% in the third quarter. Scott Capital Advisors LLC now owns 738 shares of the company’s stock valued at $654,000 after acquiring an additional 17 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

LLY has been the subject of several research reports. Bank of America upped their price target on shares of Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Jefferies Financial Group boosted their target price on Eli Lilly and Company from $994.00 to $1,015.00 and gave the company a “buy” rating in a report on Monday, June 24th. Truist Financial upped their price target on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a “buy” rating in a research note on Thursday. Citigroup assumed coverage on shares of Eli Lilly and Company in a research report on Friday, September 13th. They issued a “buy” rating and a $1,060.00 price objective on the stock. Finally, Morgan Stanley restated an “overweight” rating and set a $1,106.00 price objective on shares of Eli Lilly and Company in a research report on Tuesday, August 27th. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $979.29.

Eli Lilly and Company Price Performance

NYSE LLY traded up $15.34 during trading hours on Friday, reaching $926.03. The company’s stock had a trading volume of 1,231,814 shares, compared to its average volume of 3,004,167. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11. The stock has a market cap of $880.13 billion, a PE ratio of 113.34, a PEG ratio of 2.79 and a beta of 0.42. The company’s 50-day moving average is $908.28 and its two-hundred day moving average is $851.21. Eli Lilly and Company has a fifty-two week low of $547.61 and a fifty-two week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, topping analysts’ consensus estimates of $2.64 by $1.28. The business had revenue of $11.30 billion during the quarter, compared to analysts’ expectations of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. Analysts forecast that Eli Lilly and Company will post 16.49 EPS for the current year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.